Pulse Biosciences, Inc., a clinical-stage medical technology company headquartered in Hayward, California, disclosed in a US Securities and Exchange Commission filing that the company and several of its directors have received subpoenas from the SEC. According to Pulse, the SEC is seeking information about trading of the company’s stock in advance of the financing announcement made by the company in September 2017. Pulse says that it is cooperating with the investigation.
March 14, 2019
Medical technology company discloses SEC investigation
Related by Topic
Florida executive charged with insider trading in the Southern District of New York
August 28, 2026
News Alert
Senior Director of Operations charged with insider trading in the Southern District of New York
August 20, 2026
News Alert
SEC dismisses insider trading case against former healthcare CEO
August 17, 2026
News Alert